MPPI

Multicare Pharmaceuticals Philippines, Inc. (MPPI) is a leading pharmaceutical company based in the Philippines that specializes in the marketing, distribution, and sale of innovative branded and generic therapeutic products. Established in 2001, the company has developed a robust presence in the Philippine healthcare market through strategic partnerships with global pharmaceutical firms to launch research-based medicines and medical devices. A cornerstone of its current portfolio is the commercialization of Tegoprazan, a novel potassium-competitive acid blocker (P-CAB) used for treating gastrointestinal disorders. In 2024, the global pharmaceutical major Lupin Limited initiated a strategic acquisition to take full ownership of MPPI, aiming to strengthen its footprint in Southeast Asia. The company operates across several key therapeutic segments, including gastroenterology, cardiology, women's health, and pediatrics.